Literature DB >> 35821468

A Simple Bioluminescent Assay for the Screening of Cytotoxic Molecules Against the Intracellular Form of Leishmania infantum.

Diego Benítez1, Andrea Medeiros2,3, Cristina Quiroga2, Marcelo A Comini4.   

Abstract

This chapter describes a viability assay for the intracellular (amastigote) and clinically relevant form of Leishmania infantum that is based on the detection of bioluminescence (BL) signal. The assay uses a reporter cell line of L. infantum that expresses constitutively a redshifted luciferase from Photinus pyralis and murine macrophages (cell line J774.A1) as host cells for infection. The host cell line was selected because it is a differentiated cell line, easy to manipulate in vitro, and advantageous for ethical reasons. This chapter introduces an assay designed for the screening of bioactive compounds/molecules employing a 96-well microplate and a 24 h treatment. The assay setup shows excellent balance between simplicity (cell culture manipulation/infection and timing) and quality parameters, as well as potential to detect drug-like molecules acting in a fast and cytotoxic manner.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Drug discovery; Leishmania infantum; Redshifted luciferase; Viability assay; Visceral leishmaniasis

Mesh:

Substances:

Year:  2022        PMID: 35821468     DOI: 10.1007/978-1-0716-2453-1_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  32 in total

Review 1.  Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections.

Authors:  Rob Don; Jean-Robert Ioset
Journal:  Parasitology       Date:  2013-08-28       Impact factor: 3.234

2.  High-content assay for measuring intracellular growth of Leishmania in human macrophages.

Authors:  Michael J Dagley; Eleanor C Saunders; Kaylene J Simpson; Malcolm J McConville
Journal:  Assay Drug Dev Technol       Date:  2015-08-06       Impact factor: 1.738

3.  Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.

Authors:  Manu De Rycker; Irene Hallyburton; John Thomas; Lorna Campbell; Susan Wyllie; Dhananjay Joshi; Scott Cameron; Ian H Gilbert; Paul G Wyatt; Julie A Frearson; Alan H Fairlamb; David W Gray
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

4.  An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages.

Authors:  Jair L Siqueira-Neto; Seunghyun Moon; Jiyeon Jang; Gyongseon Yang; Changbok Lee; Hong Kee Moon; Eric Chatelain; Auguste Genovesio; Jonathan Cechetto; Lucio H Freitas-Junior
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

5.  A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit.

Authors:  Geraldine De Muylder; Kenny K H Ang; Steven Chen; Michelle R Arkin; Juan C Engel; James H McKerrow
Journal:  PLoS Negl Trop Dis       Date:  2011-07-19

6.  Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.

Authors:  S Lamotte; N Aulner; G F Späth; E Prina
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

7.  High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery.

Authors:  Nathalie Aulner; Anne Danckaert; Eline Rouault-Hardoin; Julie Desrivot; Olivier Helynck; Pierre-Henri Commere; Hélène Munier-Lehmann; Gerald F Späth; Spencer L Shorte; Geneviève Milon; Eric Prina
Journal:  PLoS Negl Trop Dis       Date:  2013-04-04

8.  The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases.

Authors:  Peter J Hotez; Miriam Alvarado; María-Gloria Basáñez; Ian Bolliger; Rupert Bourne; Michel Boussinesq; Simon J Brooker; Ami Shah Brown; Geoffrey Buckle; Christine M Budke; Hélène Carabin; Luc E Coffeng; Eric M Fèvre; Thomas Fürst; Yara A Halasa; Rashmi Jasrasaria; Nicole E Johns; Jennifer Keiser; Charles H King; Rafael Lozano; Michele E Murdoch; Simon O'Hanlon; Sébastien D S Pion; Rachel L Pullan; Kapa D Ramaiah; Thomas Roberts; Donald S Shepard; Jennifer L Smith; Wilma A Stolk; Eduardo A Undurraga; Jürg Utzinger; Mengru Wang; Christopher J L Murray; Mohsen Naghavi
Journal:  PLoS Negl Trop Dis       Date:  2014-07-24

9.  Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.

Authors:  Shilpi Khare; Advait S Nagle; Agnes Biggart; Yin H Lai; Fang Liang; Lauren C Davis; S Whitney Barnes; Casey J N Mathison; Elmarie Myburgh; Mu-Yun Gao; J Robert Gillespie; Xianzhong Liu; Jocelyn L Tan; Monique Stinson; Ianne C Rivera; Jaime Ballard; Vince Yeh; Todd Groessl; Glenn Federe; Hazel X Y Koh; John D Venable; Badry Bursulaya; Michael Shapiro; Pranab K Mishra; Glen Spraggon; Ansgar Brock; Jeremy C Mottram; Frederick S Buckner; Srinivasa P S Rao; Ben G Wen; John R Walker; Tove Tuntland; Valentina Molteni; Richard J Glynne; Frantisek Supek
Journal:  Nature       Date:  2016-08-08       Impact factor: 49.962

Review 10.  Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.

Authors:  Laura M Alcântara; Thalita C S Ferreira; Fernanda R Gadelha; Danilo C Miguel
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-09-28       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.